Webinar sponsored by the NIDA Clinical Coordinating Center, May 11, 2011.
Larissa Mooney, MD (Integrated Substance Abuse Programs, UCLA, PR Node), Andrew J. Saxon, MD (VA Puget Sound Health Care System, PN Node), Walter Ling, MD (Integrated Substance Abuse Programs, UCLA, PR Node).
This protocol-specific training webinar, hosted by the NIDA Clinical Coordinating Center, provides an overview of the National Drug Abuse Treatment Clinical Trials Network (CTN) study, protocol CTN-0048 (Cocaine Use Reduction with Buprenorphine (CURB)). This study is a randomized, double-blind, placebo-controlled trial designed to examine the safety and effectiveness of buprenorphine in the presence of naltrexone for individuals with cocaine dependence and past-year opioid dependence, past-year opioid abuse, or past-year opioid use with a history of opioid dependence during the participant's lifetime. The study background and rationale are discussed, along with the mechanisms of action of cocaine and opioids, and the effects of withdrawal from both substances. Also included are participant eligibility criteria, a list of study assessments, and detailed information about the study medications -- buprenorphine (as Suboxone®) and naltrexone (as Vivitrol®) -- and the dosing specifics that will be used in the trial. (Video, WMV/PDF, English, 2011)
Keywords: CTP training | Buprenorphine/Naloxone | Cocaine | Opioid dependence | Naltrexone | Pharmacological therapy | Suboxone | Training
Document No: 677
Submitted by Christie Thomas, MPH, Project Director, PR Node, 5/17/2011.